<DOC>
	<DOCNO>NCT00306618</DOCNO>
	<brief_summary>This single-center , open-label , phase 2 study evaluate anti-tumor activity , well safety pharmacokinetics , Panzem ( 2-methoxyestradiol , 2ME2 ) Nanocrystal Colloidal Dispersion ( NCD ) administer patient recurrent glioblastoma multiforme ( GBM )</brief_summary>
	<brief_title>Safety Efficacy Study Panzem NCD Treat Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>2-methoxyestradiol</mesh_term>
	<criteria>Histologically confirm diagnosis 1st 2nd recurrent/progressive primary WHO grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) . 18 year old An interval least 2 week prior surgical resection major surgery 4 week prior radiotherapy chemotherapy ( except nitrosoureas require 6 week ) Karnofsky performance score equal great 70 % Hematocrit great 29 % , absolute neutrophil count great 1,500 cells/micro liter , platelet great 100,000 cells/ micro liter Serum creatinine le 1.5 X upper limit normal ( ULN ) , serum SGOT le 2.5 X ULN ; bilirubin less 1.5 time ULN Signed informed consent form authorization use disclosure protect health information approve IRB prior patient entry Agree use effective contraceptive method Current , active systemic bleeding excessive risk bleed Be pregnant lactating ; employ effective birth control Concurrent severe and/or uncontrolled medical disease Impairment gastrointestinal ( GI ) function/disease Requirement therapy coumadin ( warfarin sodium ) Patient le 5 year free another primary malignancy Patients unwilling unable comply protocol Grade 2 great peripheral sensory neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>